Flaws in a tumor’s genetic mending kit drive treatment response to … – EurekAlert (press release)
EurekAlert (press release) |
Flaws in a tumor’s genetic mending kit drive treatment response to …
EurekAlert (press release) In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called ‘mismatch repair’ genetic defects, scientists … |
EurekAlert (press release) |
Flaws in a tumor’s genetic mending kit drive treatment response to …
EurekAlert (press release) In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called ‘mismatch repair’ genetic defects, scientists … |
|
Flaws in a Tumor’s Genetic Mending Kit Drive Treatment Response to Immunotherapy
Newswise (press release) “Our study results may lead to a new standard-of-care that includes mismatch repair deficiency testing to help identify a wider group of patients who have failed other therapies but may benefit from immunotherapy drugs.” says Dung Le, M.D., oncologist … |
Muscular Dystrophy News |
Gene Therapy Shows Long–Lasting Effects in Animal Model of Myotubular Myopathy
Muscular Dystrophy News A gene therapy treatment may restore the genetic mutations of myotubular myopathy, a type of muscular dystrophy that affects the skeletal muscles. In a previous study, a team of researchers at the University of Washington School of Medicine in Seattle … |
TheStreet.com |
Inovio’s HPV Immunotherapy Moves to Phase III, Stock Rises
Zacks.com Inovio Pharmaceuticals, Inc’s (INO – Free Report) shares rose over 10% after the company initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human … Inovio Begins Phase 3 Clinical Trial Of VGX-3100 For The Treatment Of HPV-Related Cervical Pre-CancerClinical Leader FDA lifts clinical hold on HPV vaccine trialThe Pharma Letter (registration) |
TheStreet.com |
Inovio’s HPV Immunotherapy Moves to Phase III, Stock Rises
Zacks.com Inovio Pharmaceuticals, Inc’s (INO – Free Report) shares rose over 10% after the company initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human … Inovio Begins Phase 3 Clinical Trial Of VGX-3100 For The Treatment Of HPV-Related Cervical Pre-CancerClinical Leader FDA lifts clinical hold on HPV vaccine trialThe Pharma Letter (registration) |